FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385622189> ?p ?o ?g. }

• W4385622189 endingPage "e069176" @default.
• W4385622189 startingPage "e069176" @default.
• W4385622189 abstract "Introduction There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. Methods and analysis PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid). Eligibility criteria: community-dwelling within 5 days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18–49 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial. Ethics and dissemination Ethical approval granted by South Central–Berkshire REC number: 21/SC/0393; IRAS project ID: 1004274. Results will be presented to policymakers and at conferences, and published in peer-reviewed journals. Trial registration number ISRCTN30448031 ; EudraCT number: 2021-005748-31." @default.
• W4385622189 created "2023-08-08" @default.
• W4385622189 creator A5000868546 @default.
• W4385622189 creator A5001664811 @default.
• W4385622189 creator A5002152360 @default.
• W4385622189 creator A5002227290 @default.
• W4385622189 creator A5002812932 @default.
• W4385622189 creator A5005853376 @default.
• W4385622189 creator A5008167189 @default.
• W4385622189 creator A5011449104 @default.
• W4385622189 creator A5013344503 @default.
• W4385622189 creator A5013729992 @default.
• W4385622189 creator A5013802638 @default.
• W4385622189 creator A5019910459 @default.
• W4385622189 creator A5022525482 @default.
• W4385622189 creator A5023150296 @default.
• W4385622189 creator A5023574292 @default.
• W4385622189 creator A5028199839 @default.
• W4385622189 creator A5028427544 @default.
• W4385622189 creator A5029134034 @default.
• W4385622189 creator A5030239949 @default.
• W4385622189 creator A5033241396 @default.
• W4385622189 creator A5033411775 @default.
• W4385622189 creator A5034507700 @default.
• W4385622189 creator A5034961076 @default.
• W4385622189 creator A5041365930 @default.
• W4385622189 creator A5044276903 @default.
• W4385622189 creator A5045695482 @default.
• W4385622189 creator A5046032964 @default.
• W4385622189 creator A5055714748 @default.
• W4385622189 creator A5057054298 @default.
• W4385622189 creator A5058496095 @default.
• W4385622189 creator A5058624862 @default.
• W4385622189 creator A5060357589 @default.
• W4385622189 creator A5068530075 @default.
• W4385622189 creator A5069076021 @default.
• W4385622189 creator A5069317379 @default.
• W4385622189 creator A5074100156 @default.
• W4385622189 creator A5075574916 @default.
• W4385622189 creator A5076869670 @default.
• W4385622189 creator A5079121335 @default.
• W4385622189 creator A5079149152 @default.
• W4385622189 creator A5079899525 @default.
• W4385622189 creator A5080610056 @default.
• W4385622189 creator A5081540134 @default.
• W4385622189 creator A5081748396 @default.
• W4385622189 creator A5083361773 @default.
• W4385622189 creator A5085878666 @default.
• W4385622189 creator A5086200154 @default.
• W4385622189 creator A5089167457 @default.
• W4385622189 date "2023-08-01" @default.
• W4385622189 modified "2023-10-17" @default.
• W4385622189 title "Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease" @default.
• W4385622189 cites W1990166011 @default.
• W4385622189 cites W2013564592 @default.
• W4385622189 cites W2086805083 @default.
• W4385622189 cites W2168416023 @default.
• W4385622189 cites W2726405642 @default.
• W4385622189 cites W2805439597 @default.
• W4385622189 cites W3001993019 @default.
• W4385622189 cites W3002696059 @default.
• W4385622189 cites W3047833576 @default.
• W4385622189 cites W3091990645 @default.
• W4385622189 cites W3135226293 @default.
• W4385622189 cites W3170964438 @default.
• W4385622189 cites W3182163984 @default.
• W4385622189 cites W3184172540 @default.
• W4385622189 cites W3185983882 @default.
• W4385622189 cites W3200797487 @default.
• W4385622189 cites W3209596279 @default.
• W4385622189 cites W4200051875 @default.
• W4385622189 cites W4200487269 @default.
• W4385622189 cites W4210642183 @default.
• W4385622189 cites W4226248511 @default.
• W4385622189 cites W4226479499 @default.
• W4385622189 cites W4229038932 @default.
• W4385622189 cites W4285719527 @default.
• W4385622189 cites W4286009332 @default.
• W4385622189 cites W4312134853 @default.
• W4385622189 cites W4312580289 @default.
• W4385622189 doi "https://doi.org/10.1136/bmjopen-2022-069176" @default.
• W4385622189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37550022" @default.
• W4385622189 hasPublicationYear "2023" @default.
• W4385622189 type Work @default.
• W4385622189 citedByCount "1" @default.
• W4385622189 countsByYear W43856221892023 @default.
• W4385622189 crossrefType "journal-article" @default.
• W4385622189 hasAuthorship W4385622189A5000868546 @default.
• W4385622189 hasAuthorship W4385622189A5001664811 @default.
• W4385622189 hasAuthorship W4385622189A5002152360 @default.
• W4385622189 hasAuthorship W4385622189A5002227290 @default.
• W4385622189 hasAuthorship W4385622189A5002812932 @default.
• W4385622189 hasAuthorship W4385622189A5005853376 @default.
• W4385622189 hasAuthorship W4385622189A5008167189 @default.
• W4385622189 hasAuthorship W4385622189A5011449104 @default.
• W4385622189 hasAuthorship W4385622189A5013344503 @default.
• W4385622189 hasAuthorship W4385622189A5013729992 @default.
• W4385622189 hasAuthorship W4385622189A5013802638 @default.

• next